114 related articles for article (PubMed ID: 15456243)
1. Structure-based discovery of nonpeptidic small organic compounds to block the T cell response to myelin basic protein.
Koehler NK; Yang CY; Varady J; Lu Y; Wu XW; Liu M; Yin D; Bartels M; Xu BY; Roller PP; Long YQ; Li P; Kattah M; Cohn ML; Moran K; Tilley E; Richert JR; Wang S
J Med Chem; 2004 Oct; 47(21):4989-97. PubMed ID: 15456243
[TBL] [Abstract][Full Text] [Related]
2. Structural basis for the binding of an immunodominant peptide from myelin basic protein in different registers by two HLA-DR2 proteins.
Li Y; Li H; Martin R; Mariuzza RA
J Mol Biol; 2000 Nov; 304(2):177-88. PubMed ID: 11080454
[TBL] [Abstract][Full Text] [Related]
3. Exploring myelin basic protein for HLA class I-binding sequences.
Tanigaki N; Fruci D; Groome N; Butler RH; Londei M; Tosi R
Eur J Immunol; 1994 Sep; 24(9):2196-202. PubMed ID: 7522167
[TBL] [Abstract][Full Text] [Related]
4. Modulation of the immune response in multiple sclerosis: production of monoclonal antibodies specific to HLA/myelin basic protein.
Puri J; Arnon R; Gurevich E; Teitelbaum D
J Immunol; 1997 Mar; 158(5):2471-6. PubMed ID: 9036999
[TBL] [Abstract][Full Text] [Related]
5. A functional and structural basis for TCR cross-reactivity in multiple sclerosis.
Lang HL; Jacobsen H; Ikemizu S; Andersson C; Harlos K; Madsen L; Hjorth P; Sondergaard L; Svejgaard A; Wucherpfennig K; Stuart DI; Bell JI; Jones EY; Fugger L
Nat Immunol; 2002 Oct; 3(10):940-3. PubMed ID: 12244309
[TBL] [Abstract][Full Text] [Related]
6. Identification of non-phosphate-containing small molecular weight inhibitors of the tyrosine kinase p56 Lck SH2 domain via in silico screening against the pY + 3 binding site.
Huang N; Nagarsekar A; Xia G; Hayashi J; MacKerell AD
J Med Chem; 2004 Jul; 47(14):3502-11. PubMed ID: 15214778
[TBL] [Abstract][Full Text] [Related]
7. Blood CD8+ T cell responses against myelin determinants in multiple sclerosis and healthy individuals.
Berthelot L; Laplaud DA; Pettré S; Ballet C; Michel L; Hillion S; Braudeau C; Connan F; Lefrère F; Wiertlewski S; Guillet JG; Brouard S; Choppin J; Soulillou JP
Eur J Immunol; 2008 Jul; 38(7):1889-99. PubMed ID: 18506883
[TBL] [Abstract][Full Text] [Related]
8. Molecular dynamics at the receptor level of immunodominant myelin basic protein epitope 87-99 implicated in multiple sclerosis and its antagonists altered peptide ligands: triggering of immune response.
Mantzourani ED; Platts JA; Brancale A; Mavromoustakos TM; Tselios TV
J Mol Graph Model; 2007 Sep; 26(2):471-81. PubMed ID: 17392002
[TBL] [Abstract][Full Text] [Related]
9. T-cell epitopes of the La/SSB autoantigen: prediction based on the homology modeling of HLA-DQ2/DQ7 with the insulin-B peptide/HLA-DQ8 complex.
Kosmopoulou A; Vlassi M; Stavrakoudis A; Sakarellos C; Sakarellos-Daitsiotis M
J Comput Chem; 2006 Jul; 27(9):1033-44. PubMed ID: 16639700
[TBL] [Abstract][Full Text] [Related]
10. Identification of small-molecule inhibitors against human leukocyte antigen-death receptor 4 (HLA-DR4) through a comprehensive strategy.
Liu Z; Li B; Li X; Zhang L; Lai L
J Chem Inf Model; 2011 Feb; 51(2):326-34. PubMed ID: 21284404
[TBL] [Abstract][Full Text] [Related]
11. The autoimmune TCR-Ob.2F3 can bind to MBP85-99/HLA-DR2 having an unconventional mode as in TCR-Ob.1A12.
Kato Z; Stern JN; Nakamura HK; Miyashita N; Kuwata K; Kondo N; Strominger JL
Mol Immunol; 2010; 48(1-3):314-20. PubMed ID: 20810170
[TBL] [Abstract][Full Text] [Related]
12. Design of protease-resistant myelin basic protein-derived peptides by cleavage site directed amino acid substitutions.
Burster T; Marin-Esteban V; Boehm BO; Dunn S; Rotzschke O; Falk K; Weber E; Verhelst SH; Kalbacher H; Driessen C
Biochem Pharmacol; 2007 Nov; 74(10):1514-23. PubMed ID: 17803968
[TBL] [Abstract][Full Text] [Related]
13. A peptidomimetic that specifically inhibits human leukocyte antigen DRB1*0401-restricted T cell proliferation.
Woulfe SL; Bono CP; Zacheis ML; Welply JK; Kirschmann DA; Baudino TA; Wang Y; Stone DA; Hanson GJ; Vuletich JL; Bedell LJ; Schwartz BD; Howard SC
J Pharmacol Exp Ther; 1997 May; 281(2):663-9. PubMed ID: 9152371
[TBL] [Abstract][Full Text] [Related]
14. A double mutation of MBP(83-99) peptide induces IL-4 responses and antagonizes IFN-gamma responses.
Katsara M; Yuriev E; Ramsland PA; Deraos G; Tselios T; Matsoukas J; Apostolopoulos V
J Neuroimmunol; 2008 Aug; 200(1-2):77-89. PubMed ID: 18675465
[TBL] [Abstract][Full Text] [Related]
15. HLA and leprosy in the pre and postgenomic eras.
Geluk A; Ottenhoff TH
Hum Immunol; 2006 Jun; 67(6):439-45. PubMed ID: 16728267
[TBL] [Abstract][Full Text] [Related]
16. Discovering potassium channel blockers from synthetic compound database by using structure-based virtual screening in conjunction with electrophysiological assay.
Liu H; Gao ZB; Yao Z; Zheng S; Li Y; Zhu W; Tan X; Luo X; Shen J; Chen K; Hu GY; Jiang H
J Med Chem; 2007 Jan; 50(1):83-93. PubMed ID: 17201412
[TBL] [Abstract][Full Text] [Related]
17. Electron paramagnetic resonance spectroscopy and molecular modelling of the interaction of myelin basic protein (MBP) with calmodulin (CaM)-diversity and conformational adaptability of MBP CaM-targets.
Polverini E; Boggs JM; Bates IR; Harauz G; Cavatorta P
J Struct Biol; 2004 Dec; 148(3):353-69. PubMed ID: 15522783
[TBL] [Abstract][Full Text] [Related]
18. Induction of EBV-latent membrane protein 1-specific MHC class II-restricted T-cell responses against natural killer lymphoma cells.
Kobayashi H; Nagato T; Takahara M; Sato K; Kimura S; Aoki N; Azumi M; Tateno M; Harabuchi Y; Celis E
Cancer Res; 2008 Feb; 68(3):901-8. PubMed ID: 18245493
[TBL] [Abstract][Full Text] [Related]
19. Generation of functional HLA-DR*1101 tetramers receptive for loading with pathogen- or tumour-derived synthetic peptides.
Moro M; Cecconi V; Martinoli C; Dallegno E; Giabbai B; Degano M; Glaichenhaus N; Protti MP; Dellabona P; Casorati G
BMC Immunol; 2005 Dec; 6():24. PubMed ID: 16329759
[TBL] [Abstract][Full Text] [Related]
20. Possibilities and limitations in the rational design of modified peptides for T cell mediated immunotherapy.
de Haan EC; Moret EE; Wagenaar-Hilbers JP; Liskamp RM; Wauben MH
Mol Immunol; 2005 Feb; 42(3):365-73. PubMed ID: 15589325
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
